Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;27(1):585-598.
doi: 10.1080/10717544.2020.1748758.

Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source

Wanrong Meng  1 , Chanshi He  1 , Yaying Hao  1 , Linlin Wang  1 , Ling Li  1 , Guiquan Zhu  1
Affiliations
Review

Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source

Wanrong Meng et al. Drug Deliv. 2020 Dec.

Abstract

Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, are nanosized membrane vesicles derived from most cell types. Carrying diverse biomolecules from their parent cells, EVs are important mediators of intercellular communication and thus play significant roles in physiological and pathological processes. Owing to their natural biogenesis process, EVs are generated with high biocompatibility, enhanced stability, and limited immunogenicity, which provide multiple advantages as drug delivery systems (DDSs) over traditional synthetic delivery vehicles. EVs have been reported to be used for the delivery of siRNAs, miRNAs, protein, small molecule drugs, nanoparticles, and CRISPR/Cas9 in the treatment of various diseases. As a natural drug delivery vectors, EVs can penetrate into the tissues and be bioengineered to enhance the targetability. Although EVs' characteristics make them ideal for drug delivery, EV-based drug delivery remains challenging, due to lack of standardized isolation and purification methods, limited drug loading efficiency, and insufficient clinical grade production. In this review, we summarized the current knowledge on the application of EVs as DDS from the perspective of different cell origin and weighted the advantages and bottlenecks of EV-based DDS.

Keywords: Drug delivery; exosomes; extracellular vesicles; microvesicles.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Scheme of biogenesis of three types of extracellular vesicles (exosomes, microvesicles, and apoptotic bodies) and component of exosome. Exosomes are cell secreted vesicles of ∼100 nm in size and packed with a variety of cellular components including mRNAs, miRNAs, proteins, enzymes, lipids, carbohydrates, etc. The exosome surface is decorated with various membrane proteins responsible for different pathophysiological functions.
Figure 2.
Figure 2.
Scheme of the potential of EVs in disease treatment and drug delivery. EVs can be isolated from different ‘factories’ (dendritic cells, mesenchymal stem cells, macrophages, milk, tumor cells, others), loading different cargos (small molecules, nucleic acids, protein, metal nanoparticles), and targeting to precise disease (cardiovascular disease, neurodegenerative disease, osteoporosis, cancer, malignancies, and metastasis).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Admyre C, Johansson SM, Qazi KR, et al. (2007). Exosomes with immune modulatory features are present in human breast milk. J Immunol 179:1969–78. - PubMed
    1. Agrawal AK, Aqil F, Jeyabalan J, et al. (2017). Milk-derived exosomes for oral delivery of paclitaxel. Nanomedicine 13:1627–36. - PubMed
    1. Akao Y, Iio A, Itoh T, et al. (2011). Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther 19:395–9. - PMC - PubMed
    1. Alderton GK. (2012). Exosomes drive premetastatic niche formation. Nat Rev Cancer 12:447. - PubMed
    1. Allen TM, Cullis PR. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36–48. - PubMed

Grants and funding

This work was supported by the National Natural Science Foundation of China [Grant Nos. 81672690, 81772900, 81872196, and 81972541] and the Department of Science and Technology of Sichuan Province [Grant No. 2018JY0646].